Posts

Posted on

Wolters Kluwer Tax & Accounting CEO Karen Abramson once again recognized as one of the Most Powerful Women in Accounting

Wolters Kluwer Tax & Accounting CEO Karen Abramson once again recognized as one of the Most Powerful Women in Accounting

NEW YORK–(BUSINESS WIRE)–Wolters Kluwer Tax & Accounting CEO Karen Abramson has been named among 25 most powerful women in the accounting profession by the American Institute of CPAs (AICPA) and CPA Practice Advisor. This is the sixth time Abramson has earned a spot on the list that recognizes female leaders who are making the greatest impact on the tax and accounting profession.

As the CEO of Wolters Kluwer Tax & Accounting, a leading provider of software solutions and local expertise that helps tax, accounting, and audit professionals research and navigate complex regulations, comply with legislation, manage their businesses and advise clients with speed, accuracy, and efficiency, Abramson leads more than 6,600 employees worldwide across North America, Europe, AsiaPacific, and Brazil. Since joining the Tax & Accounting division, Karen Abramson has launched award-winning products, held global customer forums, and driven technology and innovation across the organization.

What sets Abramson apart as a leader is her understanding that the key to success lies at the nexus of operation and strategy – a strategy without the ability to execute is like having no strategy at all. She continues to build a global vision, a strong strategy driven by customer insights, and the processes to drive execution.

A group of independent judges reviewed the nominations and selected those who best embodied the following characteristics:

  • Being a driving force for innovation and excellence
  • Demonstrably contributing to the success of their own organization and the accounting profession as a whole
  • Providing guidance and leadership to contribute to the growth of the profession
  • Effectively representing the accounting profession through civic and community outreach

“This year’s group of winners are an excellent example of the impact that women are making throughout the profession,” said Gail Perry, editor-in-chief, CPA Practice Advisor. “These leaders serve as an inspiration to a generation of women who are starting their career in the profession.”

In addition to being honored by CPA Practice Advisor for a sixth time, Abramson’s past accomplishments include recognitions by the Stevie Women in Business Awards, by the SIIA CODiE Awards, and being named by Accounting Today as one of the Top 100 Most Influential People in Accounting.

About Wolters Kluwer Tax & Accounting

Wolters Kluwer Tax & Accounting is a leading provider of software solutions and local expertise that helps tax, accounting, and audit professionals research and navigate complex regulations, comply with legislation, manage their businesses and advise clients with speed, accuracy, and efficiency.

Wolters Kluwer Tax & Accounting is part of Wolters Kluwer (WKL), a global leader in professional information, software solutions, and services for the healthcare; tax and accounting; governance, risk and compliance; and legal and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2019 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.

MARISA WESTCOTT

212-771-0853

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Professional Services Data Management Technology Finance Software Accounting

MEDIA:

Logo
Logo
Posted on

Veolia North America Acquires Boston-Based Meter-Reading Company

Veolia North America Acquires Boston-Based Meter-Reading Company

Acquisition of Energenix makes Veolia North America’s SourceOne the leading meter services provider in Greater Boston

BOSTON–(BUSINESS WIRE)–
Representing a growth strategy focused on clean energy, Veolia North America, through its energy subsidiary, SourceOne Inc., has acquired Energenix, a Boston-based utility meter reading and billing service that provides services throughout Eastern Massachusetts.

The acquisition makes Veolia North America the leading provider of meter reading and billing services in the Northeast, with a portfolio of over 700 buildings and 200 customers. The offering represents a key component of the company’s growth strategy to provide advanced energy management technologies and programs to building owners, facilities managers and energy consumers throughout the region.

Energenix was created in 1994 by Guy Machnes, a former electrician who identified the need for efficient meter-reading services and steadily expanded the business over the past 26 years. Machnes recognized that in SourceOne he had found an experienced partner with the capabilities to offer technological advances and added services that will enhance the Energenix customer’s experience. SourceOne’s expertise in engineering services, design, implementation and maintenance of metering systems for a variety of utilities adds intrinsic value to the offering.

“We are excited to welcome Energenix into the SourceOne family,” said Matt Madeksza, Veolia North America President and CEO. “With this acquisition, we are strengthening our position as a trusted provider of energy services where innovation and vision lead to greater efficiency and sustainability.”

About Veolia North America

A subsidiary of Veolia group, Veolia North America (VNA) offers a full spectrum of water, waste and energy management services, including water and wastewater treatment, commercial and hazardous waste collection and disposal, heating and cooling networks, energy consulting and resource recovery. VNA helps commercial, industrial, healthcare, higher education and municipality customers throughout North America. Headquartered in Boston, Mass., Veolia North America has more than 7,000 employees working at more than 150 locations across the continent. www.veolianorthamerica.com

About Veolia

Veolia groupis the global leader in optimized resource management. With nearly 179,000 employees worldwide, the Group designs and provides water, waste and energy management solutions which contribute to the sustainable development of communities and industries. Through its three complementary business activities, Veolia helps to develop access to resources, preserve available resources, and to replenish them. In 2019, the Veolia group supplied 98 million people with drinking water and 67 million people with wastewater service, produced nearly 45 million megawatt hours of energy and treated 50 million metric tons of waste. Veolia Environnement (listed on Paris Euronext: VIE) recorded consolidated revenue of €27.189 billion in 2019 (USD 29.9 billion). www.veolia.com

Matt Burgard

(203) 859-4168

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Other Energy Utilities Environment Other Construction & Property Alternative Energy Energy Construction & Property

MEDIA:

Posted on

Henry Schein Announces Participation in Upcoming Virtual Conferences in December

Henry Schein Announces Participation in Upcoming Virtual Conferences in December

MELVILLE, N.Y.–(BUSINESS WIRE)–
Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following virtual investor conferences in December:

  • Piper Sandler 32nd Annual Healthcare Conference on December 1, 2020, at 1:00 p.m. Eastern time.
  • Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 2, 2020, at 10:30 a.m. Eastern time.
  • Nasdaq 43rd Virtual Investor Conference on December 4, 2020, at 11:30 a.m. Eastern time.

Henry Schein’s presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on the Henry Schein website following the presentations.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 19,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional healthcare clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 31 countries. The Company’s sales from continuing operations reached $10.0 billion in 2019, and have grown at a compound annual rate of approximately 13 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, and @HenrySchein on Twitter.

Steven Paladino

Executive Vice President and CFO

[email protected]

(631) 843-5500

or

Carolynne Borders

Vice President, Investor Relations

[email protected]

(631) 390-8105

Media: Ann Marie Gothard

Vice President, Corporate Media Relations

[email protected]

(631) 390-8169

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Other Health Health Dental Practice Management Medical Supplies

MEDIA:

Logo
Logo
Posted on

NeuBase Therapeutics Announces Addition of Eriks Rozners, Ph.D. and Randy Davis, MBA to Scientific Advisory Board

PITTSBURGH, Nov. 17, 2020 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced the addition of Eriks Rozners, Ph.D. and Randy Davis, MBA to its scientific advisory board (SAB). Dr. Rozners, an expert in nucleic acid biochemistry, and Mr. Davis, a biotechnology industry veteran, bring extensive experience to NeuBase.

“We are thrilled to welcome Eriks and Randy to the NeuBase scientific advisory board. Their unique perspectives gained over their distinctive careers will undoubtedly provide valuable insight and complement our team of renowned experts,” said Dietrich A. Stephan, Ph.D., chief executive officer of NeuBase. “We believe that our platform, which relies on elegant peptide nucleic acid chemistry, is first in class and has the potential to change the treatment landscape for a range of genetic conditions, both common and rare. We are honored that Eriks, a leading expert in developing technologies which scan duplex genomic targets without invasion via triplex binding so as to co-localize pharmacophores with their targets, recognizes this, and we are eager to leverage his unparalleled knowledge as we optimize our PATrOL™ platform. Additionally, Randy’s extensive experience in semiconductor-based single molecule nucleic acid sequencing perfectly complements the strengths of each member of our SAB and brings atomic-scale measurement capabilities to the company. We look forward to benefiting from his vast knowledge as we continue to advance our PATrOL-enabled therapies under the guidance of our outstanding group of scientific advisors.”

Dr. Eriks Rozners is a leading expert in the chemistry and biochemistry of nucleic acids and brings his expertise to NeuBase as the Company is optimizing and developing its PATrOL platform. He is a professor and the chairman of the Department of Chemistry at Binghamton University, where his lab focuses on the use of organic chemistry to develop unique model systems and tools for the studies and practical applications of nucleic acid biochemistry. Dr. Rozners received a bachelor’s degree in chemical engineering and a doctorate in organic chemistry from Riga Technical University.

Mr. Randy Davis is a seasoned industry veteran with expertise in the field of biotechnology and was one of the founding members of Genia Technologies, a company developing a next-generation sequencing platform, which was acquired by Roche in 2014. In addition, he has served as a member or investor in half a dozen biotech companies and has authored or co-authored over 20 patent applications. Mr. Davis graduated from Tokyo Electrical University with a degree in electrical engineering and went on to receive an MBA from San Jose State University. In 2002, he continued his education at California State University East Bay, where he received a bachelor’s and master’s degree in molecular biology before moving on to various industry roles.

About NeuBase Therapeutics, Inc.

NeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase’s designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.

Use of Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are distinguished by use of words such as “will,” “would,” “anticipate,” “expect,” “believe,” “designed,” “plan,” or “intend,” the negative of these terms, and similar references to future periods. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those risk factors contained in our filings with the U.S. Securities and Exchange Commission, may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: the Company’s plans to develop and commercialize its product candidates; the timing of initiation of the Company’s planned clinical trials; the timing of the availability of data from the Company’s clinical trials; the timing of any planned investigational new drug application or new drug application; the Company’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company’s product candidates; the Company’s commercialization, marketing and manufacturing capabilities and strategy; global health conditions, including the impact of COVID-19; the Company’s ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risk factors contained in our filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

NeuBase Investor Contact:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]
OP: (617) 430-7576

NeuBase Media Contact:

Cait Williamson, Ph.D.
LifeSci Communications
[email protected]
OP: (646) 751-4366



Posted on

Avon Tyres Featured on Restored Evel Knievel Motorcycle

Avon Tyres Featured on Restored Evel Knievel Motorcycle

Bike recently unveiled at Evel Knievel Museum

FINDLAY, Ohio–(BUSINESS WIRE)–
Avon motorcycle tires have been utilized in a recent restoration of Evel Knievel’s original 1968-spec ‘American Eagle’ Laverda, a bike on which Knievel made a host of jumps during the late 1960s and early 1970s. The famous stunt performer’s refurbished motorcycle was unveiled Nov. 6 at the Evel Knievel Museum in Topeka, Kansas. Avon Tyres is owned by the Cooper Tire & Rubber Company.

Restoration of the motorcycle began when Louis “Rocket” Re, a friend of the late Evel Knievel, and a stunt rider himself, tracked down the original Laverda several years ago. After receiving permission from the bike’s owner to carry out restoration work and display the vehicle at the museum, Re contacted Avon to confirm the bike’s original fitment of Avon Safety Mileage MKII tires and obtain a set of the brand’s current day Safety Mileage MKII tires as part of the restoration.

Dominic Clifford, Global Manager – Avon Motorcycle, said, “We are pleased to be involved in a restoration project that involves such an iconic motorcycle. Avon offers a line of classic tires that give motorcycles an authentic appearance with the benefit of modern-day technology. The Avon Safety Mileage MKII utilized in this restoration offers a period-look block pattern with a new compound design and the latest construction methods for exceptional grip, handling and stability.”

Re said, “This is my first experience with Avon Tyres and I really like the vintage style – I could see the quality craftsmanship right away. The like turned to love when I rode the bike with the new tires; I had great cornering traction and high-speed stability, and confidence equals a fun, safe day of riding.”

Robert Craig Knievel, known professionally as Evel Knievel, was an American stunt performer whose career spanned three decades from the 1960s to the 1980s. He attempted more than 75 ramp-to-ramp motorcycle jumps over the years, the majority of which were completed successfully. The motorcycle, which will be on display at the Museum for two years, can be viewed alongside other iconic items such as Knievel’s original Mack Truck.

For more information about Avon Tyres, visit www.avontyres.com.

About Cooper Tire & Rubber Company

Cooper Tire & Rubber Company (NYSE: CTB) is the parent company of a global family of companies that specializes in the design, manufacture, marketing and sale of passenger car, light truck, medium truck, motorcycle and racing tires. Cooper’s headquarters is in Findlay, Ohio, with manufacturing, sales, distribution, technical and design operations within its family of companies located in more than one dozen countries around the world. For more information on Cooper, visit www.coopertire.com, www.facebook.com/coopertire or www.twitter.com/coopertire.

Megan James

419-424-4251

[email protected]

KEYWORDS: Kentucky Ohio United States North America

INDUSTRY KEYWORDS: Other Sports Motorcycles Arts/Museums Extreme Sports Entertainment Automotive Manufacturing Manufacturing Automotive Celebrity Sports Motor Sports Other Manufacturing Tires & Rubber Performance & Special Interest

MEDIA:

Posted on

FLIR Systems Announces Industry-First Thermal and Visible Videoscope for Underground Utility Vaults

FLIR Systems Announces Industry-First Thermal and Visible Videoscope for Underground Utility Vaults

New FLIR VS290-32 Offers a Dual-Sensor, Electrical Safety-Rated Videoscope for Safer and More Efficient Industrial Inspection

ARLINGTON, Va.–(BUSINESS WIRE)–
FLIR Systems, Inc. (NASDAQ: FLIR) today announced the FLIR VS290-32™, an industry-first, videoscope that combines thermal imaging and a visible camera specifically designed for safer and more efficient inspections of hard-to-reach underground utility vaults. The VS290-32 is the company’s first industrial-grade, electrical safety-rated, flexible dual-sensor videoscope on a replaceable, two-meter-long camera probe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005246/en/

The FLIR VS290-32 videoscope combines thermal imaging and a visible camera on a replaceable, two-meter-long probe for safer and more efficient inspections of vented manholes without having to remove the cover. (Photo: Business Wire)

The FLIR VS290-32 videoscope combines thermal imaging and a visible camera on a replaceable, two-meter-long probe for safer and more efficient inspections of vented manholes without having to remove the cover. (Photo: Business Wire)

For use in the most demanding environments, the VS290-32 is CAT IV 600 V safety rated for electrical inspections, along with an IP67-rated camera tip and IP54 base unit to protect against dust and water. The device features FLIR Systems’ patented Multi-Spectral Dynamic Imaging (MSX®), which improves image clarity by embossing visual scene details onto full thermal images, providing crucial context to accurately and safely assess and identify potential issues to prevent blackouts and asset failures. A low-profile tip and bright LED work light provides illumination for MSX in dark environments, including under manhole covers or in other tight spaces such as attics, within HVAC systems, and inside machinery.

“The ruggedized and electrical-safety rated videoscope with MSX will drastically increase the ease of thermal inspections within tight, hard-to-reach places at power generation plants, power distribution systems, manufacturing facilities, and for public safety, and building diagnostics inspections,” said Rickard Lindvall, General Manager, Solutions Business at FLIR Systems.

The VS290-32 features a FLIR Lepton® thermal sensor and offers the option of hot/cold color alarms, or isotherms, to quickly identify areas of concern across a temperature range from -10 to 400 degrees Celsius (14 to 752 degrees Fahrenheit). The device includes a dual battery charger along with lithium ion rechargeable batteries that each provide up to six hours of continuous use.

“Safety is Con Edison’s top priority,” said Andrew Reid, Section Manager for Engineering and Analysis in Distribution Engineering at Con Edison. “This new tool allows our crews to safely, efficiently, and effectively inspect vented manholes and identify potential problems without having to remove the cover or even having to enter the structure. This reduces the physical effort required by our crews, the time it takes to complete an inspection and enhances data collection activities to support our ongoing infrastructure planning and maintenance.”

The VS290-32 is available globally today for $4,999 through FLIR and authorized FLIR distributors. To learn more about the FLIR VS290, visit www.flir.com/VS290-32.

About FLIR Systems, Inc.

Founded in 1978, FLIR Systems is a world-leading industrial technology company focused on intelligent sensing solutions for defense and industrial applications. FLIR Systems’ vision is to be “The World’s Sixth Sense, creating technologies to help professionals make more informed decisions that save lives and livelihoods. For more information, please visit www.flir.com and follow @flir.

Media Relations:

Eleana Stayer

Phone: +44 7545 204375.

Email: [email protected]

Investor Relations:

Lasse Glassen

Addo Investor Relations

Phone: 424-238-6249

Email: [email protected]

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Hardware Manufacturing Audio/Video Technology Engineering

MEDIA:

Logo
Logo
Photo
Photo
The FLIR VS290-32 videoscope combines thermal imaging and a visible camera on a replaceable, two-meter-long probe for safer and more efficient inspections of vented manholes without having to remove the cover. (Photo: Business Wire)
Posted on

Movado Group, Inc. Announces Date of Conference Call and Webcast for Third Quarter Fiscal Year 2021 Results

Movado Group, Inc. Announces Date of Conference Call and Webcast for Third Quarter Fiscal Year 2021 Results

PARAMUS, N.J.–(BUSINESS WIRE)–
Movado Group, Inc. (NYSE: MOV) invites investors to listen to a broadcast of the Company’s conference call to discuss third quarter fiscal year 2021 earnings results on Tuesday, November 24, 2020 at 9:00 a.m. Eastern Time. A press release detailing the Company’s third quarter fiscal year 2021 results will be issued before the market opens and prior to the call. The conference call will be hosted by Efraim Grinberg, Chairman and Chief Executive Officer, and Sallie DeMarsilis, Chief Financial Officer.

Investors and analysts interested in participating to the call are invited to dial (877) 407-0784 and reference conference ID number 13713033 approximately ten minutes prior to the start of the call. The conference call will also be webcast live at www.movadogroup.com. The webcast will be archived online within one hour of the completion of the conference call and remain available for 90 days. Additionally, a telephonic re-play of the call will be available at 12:00 p.m. ET on November 24, 2020 until 11:59 p.m. ET on December 8, 2020 and can be accessed by dialing (844) 512-2921 and entering replay pin number 13713033.

Movado Group, Inc. designs, sources, and globally distributes MOVADO®, MVMT®, OLIVIA BURTON®, EBEL®, CONCORD®, COACH®, TOMMY HILFIGER®, HUGO BOSS®, LACOSTE®, SCUDERIA FERRARI®, REBECCA MINKOFF® and URI MINKOFF® watches and, for certain of these brands, jewelry and other accessories, and operates Movado Company Stores in the United States and Canada.

ICR, Inc.

Investors:

Rachel Schacter/Allison Malkin

203-682-8200

KEYWORDS: New York New Jersey United States North America

INDUSTRY KEYWORDS: Retail Luxury Fashion

MEDIA:

Posted on

Wrightspeed Drives the Future of Sustainable Trucking In Midst of COVID Pandemic

Wrightspeed Drives the Future of Sustainable Trucking In Midst of COVID Pandemic

Company answers call for cleaner urban transportation globally

ALAMEDA, Calif.–(BUSINESS WIRE)–Wrightspeed, a leading manufacturer of range-extended electric powertrains for heavy local transport, is answering the call for cleaner urban transportation as companies, cities and countries across the world build toward sustainable operations. While there has been an increased green push in the wake of COVID-19, Wrightspeed has been ahead of the curve, developing groundbreaking technology to power frequent-stop, heavy-duty buses, refuse, and delivery trucks. Wrightspeed has opened a new route for sustainable trucking by reducing greenhouse gasses, meeting regulatory needs and noise ordinances, and improving total cost of ownership.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005108/en/

The Wrightspeed Team Drives the Future of Sustainable Trucking In Midst of COVID Pandemic (Photo: Business Wire)

The Wrightspeed Team Drives the Future of Sustainable Trucking In Midst of COVID Pandemic (Photo: Business Wire)

“Our engineering innovations have set a new standard for regional transport within the industry,” said Broc TenHouten, VP of engineering, Wrightspeed. “Studies indicate that traditional medium- and heavy-duty trucks comprise only 4 percent of the total on-road vehicles, while producing 30 percent of on-road emissions and consuming 26 percent of the fuel. Wrightspeed’s electric vehicle and range-extended EV solutions can displace conventional diesel engine vehicles, creating the next generation of commercial fleets.”

The majority of the industry is working to attack long-haul trucking challenges. However, most of the heavy-duty trucks on the road are running regional routes. Wrightspeed’s solution is directly targeted at regional applications, including urban distribution, transit buses and refuse trucks. Traditional combustion engine vehicles waste an enormous amount of fuel and produce a proportionate amount of emissions while frequently starting and stopping on these regional routes. Wrightspeed’s solutions address this problem by efficiently recovering breaking energy through an advanced multi-gear electric drive system.

Fleet operators have the option to select a Wrightspeed EV or to include a range extending engine. The range-extended hybrid option ensures the required vehicle range without adding the extra weight of massive battery systems needed by other solutions. On regional schedules, the Wrightspeed range-extended solution provides a 25 percent fuel savings with measured real-world fuel savings of up to 60 percent on more aggressive driving schedules. In addition to fuel savings, annual maintenance and brake replacement can be reduced by as much as $25,000 per year on these aggressive schedules.

“The excitement over commercial vehicle electrification is not hype, it’s justified,” said Jim Meil, ACT research principal, industry analysis and project leader of ACT’s Commercial Electric Vehicle Team. “In the right applications, especially local hauling and in urban stop-and-go operations, electric powertrains can make economic sense from a TCO and ROI perspective today. Factor in governmental green-oriented regulatory initiatives plus corporate sustainability goals, and a compelling value proposition emerges that takes our market share projections on a clear upward path.”

Wrightspeed was named a 2016 World Economic Forum “Technology Pioneer” for its innovation in reducing fuel consumption, emissions, noise pollution, and maintenance costs. Most recently, the company was named a top key player in Contrive Datum Insight’s “Electric Dump Truck Analysis Report.” Wrightspeed is engaging with fleet operators and municipalities worldwide to make a global environmental impact.

“Since Wrightspeed’s inception, the company has been geared toward a cleaner and more sustainable future,” said Gilbert Passin, chief operating officer, Wrightspeed. “We are now preparing to move into mass production to meet market demand for electric short-haul transportation. The future is now.”

For more information on Wrightspeed, visit wrightspeed.com.

About Wrightspeed Inc.

Wrightspeed Inc. is a leading manufacturer of range-extended electric powertrains for heavy local transport. Its flagship product, the Route™, was designed to transcend commercial truck efficiency and performance, providing unlimited range and dramatically reduced fuel costs. Located in Silicon Valley, Wrightspeed aims to revolutionize the trucking industry with the future generation of efficient vehicle solutions across product and market segments. For more information about Wrightspeed, visit wrightspeed.com and follow on Twitter at @GOWrightspeed.

Cautionary Statement Regarding Forward-Looking Statements

All statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on our current expectations, estimates and projections about our industry, management’s beliefs, and certain assumptions made by us, all of which are subject to change. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions, and variations or negatives of these words. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement.

Donna Loughlin Michaels

LMGPR for Wrightspeed

(408) 393-5575

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Trucking Automotive Automotive Manufacturing Environment Transport Manufacturing Fleet Management

MEDIA:

Photo
Photo
The Wrightspeed Team Drives the Future of Sustainable Trucking In Midst of COVID Pandemic (Photo: Business Wire)
Posted on

Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

  • 65% Complete Response Rate at Three Months
  • Duration of Response Estimated to be 72.5% at Nine Months (12-Months from Initiation of Therapy) by Kaplan-Meier Method; Median Duration of Response was Not Reached
  • Treatment with UGN-102 was Generally Well Tolerated, with Mostly Mild to Moderate Adverse Events Reported
  • Phase 3 Pivotal Trial Evaluating UGN-102 Versus Current Standard of Care Expected to Start by Year-End

PRINCETON, N.J.–(BUSINESS WIRE)–
UroGen Pharma Ltd. (Nasdaq: URGN) today announced final topline results from the single-arm, open-label OPTIMA II Phase 2b trial evaluating the efficacy and safety of investigational UGN-102 (mitomycin) for intravesical solution in patients with low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC). As previously reported, 65% (41/63) of patients receiving UGN-102 achieved a complete response (CR) three months after the start of therapy. In this subset of patients, duration of response at nine months (12-months from start of therapy) was estimated by Kaplan-Meier analysis to be 72.5%. Median duration of response was not reached. The Company expects to initiate a Phase 3 study evaluating UGN-102 versus current standard of care by the end of the year.

Treatment with UGN-102 was generally well tolerated and the safety profile was consistent with previously reported results. In the OPTIMA II trial, the majority of the most common adverse events (≥ 10%) were reported as mild to moderate in severity and include dysuria, urinary frequency, hematuria, urinary urgency, urinary tract infection and fatigue. No treatment related serious adverse events were reported.

“The current approach to treating patients diagnosed with low-grade intermediate risk non-muscle invasive bladder cancer is surgery. In most cases, the cancer comes back and repetitive surgical intervention is required. This puts a tremendous burden on patients and their families and can even be life-threatening,” said Andrea Maddox-Smith, Chief Executive Officer, Bladder Cancer Advocacy Network. “Being able to provide patients with an alternative, non-surgical treatment option that is effective, well-tolerated and durable, would greatly benefit those in the patient community.”

Patients with LG IR-NMIBC are chronically relapsing and currently, their only treatment option is repeated transurethral resection of bladder tumors (TURBT). Some patients require multiple TURBT surgeries per year, which can lead to increased morbidity and risks associated with repetitive anesthesia. It is estimated that 80,000 people in the U.S. are treated annually for LG IR-NMIBC. This includes newly diagnosed patients and patients who have a recurrence after surgery.

“We are extremely encouraged by the OPTIMA II data and believe UGN-102 has the potential to provide a safe, durable, outpatient treatment alternative for low-grade intermediate risk non-muscle invasive bladder cancer,” said Dr. Mark Schoenberg, Chief Medical Officer at UroGen. “We look forward to the expected initiation of our Phase 3 trial this year and further exploring the potential of our innovative technology in advancing new treatments for specialty cancers and urologic diseases.”

The Company anticipates submitting the data for presentation at an upcoming medical meeting as well as potential publication in a peer-reviewed journal.

About the Phase 2b OPTIMA II Trial

OPTIMA II (OPTimized Instillation of Mitomycin for Bladder Cancer Treatment) is an open-label, single-arm, multi-center Phase 2b clinical trial of investigational agent UGN-102 (mitomycin) for intravesical solution to evaluate its safety and efficacy in patients with low-grade non-muscle invasive bladder cancer (LG NMIBC) at intermediate risk of recurrence. Intermediate risk is defined as one or two of the following: multiple tumors, solitary tumor >3 cm, or recurrence (≥ 1 occurrence of LG NMIBC within one year of the current diagnosis). Patients were to receive six weekly intravesical instillations of 75 mg UGN-102 in an office setting. The chemoablative effect of UGN-102 was assessed three months after initiation of study treatment with complete response (CR) defined as a negative endoscopic examination, negative cytology, and when indicated, a negative for-cause biopsy. Patients achieving CR were followed quarterly to 12 months after initiation of study treatment to evaluate safety, efficacy, and durability.

About UGN-102

UGN-102 (mitomycin) for intravesical solution is an investigational drug formulation of mitomycin in Phase 2b development for the treatment of low-grade intermediate risk non-muscle invasive bladder cancer. Utilizing the RTGel Technology Platform, UroGen’s proprietary sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter. The Company reported topline interim results from the Phase 2b OPTIMA II trial in May 2020 and intends to begin a Phase 3 study to further investigate UGN-102 in the treatment of this condition by year end 2020.

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s approved product, Jelmyto (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential of UroGen’s proprietary RTGel technology platform to improve therapeutic profiles of existing drugs; the potential of UGN-102 for treatment of LG IR-NMIBC; the expected initiation of the Phase 3 trial of UGN-102 in LG IR-NMIBC by the end of 2020; and the submission of UGN-102 data for presentation at an upcoming medical meeting as well as potential publication in a peer-reviewed journal. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the timing and success of clinical trials and potential safety and other complications thereof; the ability to obtain regulatory approval within the timeframe expected, or at all; the ability to maintain regulatory approval; complications associated with commercialization activities, including complications resulting from the ongoing COVID-19 pandemic; the labeling for any approved product; the scope, progress and expansion of developing and commercializing UroGen’s product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; UroGen’s ability to attract or retain key management, members of the board of directors and personnel; and any negative effects on UroGen’s business, commercialization and product development plans caused by or associated with COVID-19. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Form 10-Q filed with the SEC on November 9, 2020, and other filings that UroGen makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.

INVESTOR CONTACT:

Sara Blum Sherman

Head of Investor Relations

[email protected]

609-467-4975

MEDIA CONTACT:

Eric Van Zanten

Head of Communications

[email protected]

610-529-6219

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA:

Posted on

Dine Brands Global, Inc. Appoints John Peyton Chief Executive Officer

Dine Brands Global, Inc. Appoints John Peyton Chief Executive Officer

John Peyton, President and CEO at Realogy Franchise Group, takes new role as CEO of Dine Brands effective January 4, 2021

GLENDALE, Calif.–(BUSINESS WIRE)–
Dine Brands Global, Inc. (NYSE: DIN), the parent company of Applebee’s Neighborhood Grill + Bar® and IHOP® restaurants, announced today that John Peyton, president and chief executive officer, Realogy Franchise Group, a wholly-owned subsidiary of Realogy Holdings Corp. (NYSE: RLGY), will be the company’s new chief executive officer, effective January 4, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005393/en/

John Peyton, Dine Brands Global, Inc.’s Incoming CEO (Photo: Business Wire)

John Peyton, Dine Brands Global, Inc.’s Incoming CEO (Photo: Business Wire)

Peyton is an experienced franchise veteran who has led global, consumer franchised businesses for over 21 years, most recently at Realogy Franchise Group where he has served as president since 2016. Realogy franchises many of the most recognized brands in the real estate industry, including Better Homes and Gardens®, Real Estate, CENTURY 21®, Coldwell Banker ®, The Corcoran Group ®, ERA ®, Sotheby’s International Realty ® and Coldwell Banker Commercial ®. There he was able to drive significant growth during one of the most challenging markets in the industry’s history. John was also instrumental in transforming and revitalizing their brands through an elevated service delivery model, placing an emphasis on agility and innovation, and creating momentum and opportunity for the company, franchisees and team members.

Prior to Realogy, John spent 17 years with Starwood Hotels and Resorts Worldwide, holding various positions including Chief Marketing Officer, Senior Vice President of Global Operations and Chief Operations Officer, North America Hotel Division. During his tenure, John was responsible for both the Global and North American Food and Beverage teams, which included their on-property restaurants. He graduated from the University of Pennsylvania with a degree in English and earned an MBA in accounting and marketing from NYU’s Stern School of Business.

“We are pleased to announce that John Peyton will be joining Dine Brands as CEO starting in January 2021,” states Richard Dahl, chairman of the board. “John’s extensive background working in the hospitality industry enables him to provide outstanding leadership and guidance as Dine Brands continues to accelerate long-term growth. We greatly appreciate Steve Joyce’s leadership and considerable contributions to Dine Brands during a critical period for the company and wish him continued success.”

Peyton replaces Dine Brands CEO, Steve Joyce, who has served as CEO since September 2017.

“Dine Brands is confident in the talented executive team in place to ensure a smooth transition and Peyton’s onboarding after the first of the year,” says Dahl.

“I am honored to take on this new role to spearhead Dine’s mission and drive shareholder value of the world’s most-loved restaurant brands,” said John Peyton, CEO at Dine Brands. “Together with our team members, franchisees and suppliers, I look forward to building upon the rich history of our restaurants and further creating community in hometowns all throughout the world.”

To learn more about Dine Brands, Applebee’s or IHOP visit www.dinebrands.com.

Media Contact

Susan Nelson

Vice President, Global Communications

and Public Affairs

Dine Brands Global, Inc.

[email protected]

Investor Contact

Ken Diptee

Executive Director, IR

Dine Brands Global, Inc.

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Retail Restaurant/Bar Food/Beverage

MEDIA:

Photo
Photo
John Peyton, Dine Brands Global, Inc.’s Incoming CEO (Photo: Business Wire)
Logo
Logo